Thyroid cancer: From molecular insights to therapy (Review)

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI

Wan Y, Li G, Cui G, Duan S and Chang S: Reprogramming of thyroid cancer metabolism: From mechanism to therapeutic strategy. Mol Cancer. 24:7432025. View Article : Google Scholar

Myung SK, Lee CW, Lee J, Kim J and Kim HS: Risk factors for thyroid cancer: A hospital-based case-control study in Korean adults. Cancer Res Treat. 49:70–78. 2017. View Article : Google Scholar : PubMed/NCBI

Li M, Li Q, Zou C, Huang Q and Chen Y: Application and recent advances in conventional biomarkers for the prognosis of papillary thyroid carcinoma. Front Oncol. 15:15989342025. View Article : Google Scholar : PubMed/NCBI

Badulescu CI, Piciu D, Apostu D, Badan M and Piciu A: Follicular thyroid carcinoma-clinical and diagnostic findings in a 20-year follow up study. Acta Endocrinol (Buchar). 16:170–177. 2020. View Article : Google Scholar : PubMed/NCBI

Huai JX, Wang F, Zhang WH, Lou Y, Wang GX, Huang LJ, Sun J and Zhou XQ: Unveiling new chapters in medullary thyroid carcinoma therapy: Advances in molecular genetics and targeted treatment strategies. Front Endocrinol (Lausanne). 15:14848152024. View Article : Google Scholar : PubMed/NCBI

Cleere EF, Prunty S and O'Neill JP: Anaplastic thyroid cancer: Improved understanding of what remains a deadly disease. Surgeon. 22:e48–e53. 2024. View Article : Google Scholar : PubMed/NCBI

Singarayer R, Mete O, Perrier L, Thabane L, Asa SL, Van Uum S, Ezzat S, Goldstein DP and Sawka AM: A systematic review and meta-analysis of the diagnostic performance of BRAF V600E immunohistochemistry in thyroid histopathology. Endocr Pathol. 30:201–218. 2019. View Article : Google Scholar : PubMed/NCBI

Grabellus F, Worm K, Schmid KW and Sheu SY: The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. Thyroid. 22:377–382. 2012. View Article : Google Scholar : PubMed/NCBI

Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 24:1256–1266. 2014. View Article : Google Scholar : PubMed/NCBI

Kang N, Zhao Z, Wang Z, Ning J, Wang H, Zhang W, Ruan X, Gao M and Zheng X: METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8. Int J Biol Sci. 20:3426–3441. 2024. View Article : Google Scholar : PubMed/NCBI

Li Q, Wang Y, Meng X, Wang W, Duan F, Chen S, Zhang Y, Sheng Z, Gao Y and Zhou L: METTL16 inhibits papillary thyroid cancer tumorigenicity through m⁶A/YTHDC2/SCD1-regulated lipid metabolism. Cell Mol Life Sci. 81:812024. View Article : Google Scholar : PubMed/NCBI

Zhu J, Wang Y, Yang C, Feng Z, Huang Y, Liu P, Chen F and Deng Z: circ-PSD3 promoted proliferation and invasion of papillary thyroid cancer cells via regulating the miR-7-5p/METTL7B axis. J Recept Signal Transduct Res. 42:251–260. 2022. View Article : Google Scholar : PubMed/NCBI

Lin J, Cai B, Lin Q, Lin X, Wang B and Chen X: TLE4 downregulation identified by WGCNA and machine learning algorithm promotes papillary thyroid carcinoma progression via activating JAK/STAT pathway. J Cancer. 15:4759–4776. 2024. View Article : Google Scholar : PubMed/NCBI

Wagner M, Wuest M, Lopez-Campistrous A, Glubrecht D, Dufour J, Jans HS, Wuest F and McMullen TPW: Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer. Endocr Relat Cancer. 27:495–507. 2020. View Article : Google Scholar : PubMed/NCBI

Wen J, Lin B, Lin L, Chen Y and Wang O: KCNN4 is a diagnostic and prognostic biomarker that promotes papillary thyroid cancer progression. Aging (Albany NY). 12:16437–16456. 2020. View Article : Google Scholar : PubMed/NCBI

Wang K, Liu S, Tian Y, Liu C, Gui Z, Yu T and Zhang L: PDZK1 Interacting Protein 1 promotes the progression of papillary thyroid cancer. J Clin Endocrinol Metab. 107:2449–2461. 2022. View Article : Google Scholar : PubMed/NCBI

Qin XJ, Lin X, Xue G, Fan HL, Wang HY, Wu JF and Pei D: CXCL10 is a potential biomarker and associated with immune infiltration in human papillary thyroid cancer. Biosci Rep. 41:BSR202034592021. View Article : Google Scholar : PubMed/NCBI

Sirakriengkrai K, Tepmongkol S, Keelawat S and Techavijit U: Clinical association of CXCR4 in primary tumor of papillary thyroid cancer and response to iodine-131 treatment. Nucl Med Commun. 42:396–401. 2021. View Article : Google Scholar : PubMed/NCBI

Shen Y, Li X, Xie R, Chen Y, Hu X, Liu Y and Ma H: Expression levels of MicroRNA-300/BCL2L11 in papillary thyroid cancer and their clinical diagnostic values. Eur Surg Res. 64:342–351. 2023. View Article : Google Scholar : PubMed/NCBI

Lin L, Wen J, Lin B, Bhandari A, Zheng D, Kong L, Wang Y, Wang O and Chen Y: Immortalization up-regulated protein promotes tumorigenesis and inhibits apoptosis of papillary thyroid cancer. J Cell Mol Med. 24:14059–14072. 2020. View Article : Google Scholar : PubMed/NCBI

Guo H, Liu R, Wu J, Li S, Yao W, Xu J, Zheng C, Lu Y and Zhang H: SRPX2 promotes cancer cell proliferation and migration of papillary thyroid cancer. Clin Exp Med. 23:4825–4834. 2023. View Article : Google Scholar : PubMed/NCBI

Yan T, Qiu W, Song J, Fan Y and Yang Z: ARHGAP36 regulates proliferation and migration in papillary thyroid carcinoma cells. J Mol Endocrinol. 66:1–10. 2021. View Article : Google Scholar : PubMed/NCBI

Zhou Y, Xiang J, Bhandari A, Wen J, Lin B, Kong L and Wang O: LRRC52-AS1 is associated with clinical progression and regulates cell migration and invasion in papillary thyroid cancer. Clin Exp Pharmacol Physiol. 47:696–702. 2020. View Article : Google Scholar : PubMed/NCBI

Cheng X, Xu S, Pan J, Zheng J, Wang X, Yu H, Bao J, Xu Y, Guan H and Zhang L: MKL1 overexpression predicts poor prognosis in patients with papillary thyroid cancer and promotes nodal metastasis. J Cell Sci. 132:jcs2313992019. View Article : Google Scholar : PubMed/NCBI

Yu Y, Yu X, Fan C, Wang H, Wang R, Feng C and Guan H: Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. J Mol Med (Berl). 96:777–790. 2018. View Article : Google Scholar : PubMed/NCBI

Zhu X, Xue C, Kang X, Jia X, Wang L, Younis MH, Liu D, Huo N, Han Y, Chen Z, et al: DNMT3B-mediated FAM111B methylation promotes papillary thyroid tumor glycolysis, growth and metastasis. Int J Biol Sci. 18:4372–4387. 2022. View Article : Google Scholar : PubMed/NCBI

Chen Y, Li H, Liang W, Guo Y, Peng M, Ke W, Xiao H, Guan H and Li Y: SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer. J Cell Biochem. 122:814–826. 2021. View Article : Google Scholar : PubMed/NCBI

Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N and Hahne JC: MicroRNAs (miRNAs) and Long Non-coding RNAs (lncRNAs) as new tools for cancer therapy: First steps from bench to bedside. Target Oncol. 15:261–278. 2020. View Article : Google Scholar : PubMed/NCBI

Zhu Y, Jin L, Shi R, Li J, Wang Y, Zhang L, Liang CZ, Narayana VK, De Souza DP, Thorne RF, et al: The long noncoding RNA glycoLINC assembles a lower glycolytic metabolon to promote glycolysis. Mol Cell. 82:542–554.e6. 2022. View Article : Google Scholar : PubMed/NCBI

Peng X, Li S, Zeng A and Song L: Regulatory function of glycolysis-related lncRNAs in tumor progression: Mechanism, facts, and perspectives. Biochem Pharmacol. 229:1165112024. View Article : Google Scholar : PubMed/NCBI

Shi L, Duan R, Sun Z, Jia Q, Wu W, Wang F, Liu J, Zhang H and Xue X: LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer. Cell Death Differ. 30:1517–1532. 2023. View Article : Google Scholar : PubMed/NCBI

Qiu J, Zhang W, Zang C, Liu X, Liu F, Ge R, Sun Y and Xia Q: Identification of key genes and miRNAs markers of papillary thyroid cancer. Biol Res. 51:452018. View Article : Google Scholar : PubMed/NCBI

Liu J, Dong H, Yang Y, Qian Y, Liu J, Li Z, Guan H, Chen Z, Li C, Zhang K, et al: Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value. Future Oncol. 14:3015–3022. 2018. View Article : Google Scholar : PubMed/NCBI

Yi T, Zhou X, Sang K, Zhou J and Ge L: MicroRNA-1270 modulates papillary thyroid cancer cell development by regulating SCAI. Biomed Pharmacother. 109:2357–2364. 2019. View Article : Google Scholar : PubMed/NCBI

Sun Y, Sun W, Hua H, Zhang J, Yu Q, Wang J, Liu X and Dong A: Overexpression of miR-127 predicts poor prognosis and contributes to the progression of papillary thyroid cancer by targeting REPIN1. Horm Metab Res. 53:197–203. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Wang W, Su Z, Zhang J and Cao H: Circ_0011058 facilitates proliferation, angiogenesis and radioresistance in papillary thyroid cancer cells by positively regulating YAP1 via acting as miR-335-5p sponge. Cell Signal. 88:1101552021. View Article : Google Scholar : PubMed/NCBI

Yang Z, Li G, Ding C, Sun W and Zhang J: Long non-coding RNA HULC exerts oncogenic activity on papillary thyroid cancer in vitro and in vivo. Artif Cells Nanomed Biotechnol. 48:326–335. 2020. View Article : Google Scholar : PubMed/NCBI

Xia F, Chen Y, Jiang B, Du X, Peng Y, Wang W, Huang W, Feng T and Li X: Long Noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway. Cell Physiol Biochem. 50:1659–1672. 2018. View Article : Google Scholar : PubMed/NCBI

Jiang L, Wu Z, Meng X, Chu X, Huang H and Xu C: LncRNA HOXA-AS2 facilitates tumorigenesis and progression of papillary thyroid cancer by modulating the miR-15a-5p/HOXA3 axis. Hum Gene Ther. 30:618–631. 2019. View Article : Google Scholar : PubMed/NCBI

Lin BY, Wen JL, Zheng C, Lin LZ, Chen CZ and Qu JM: Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway. J Cell Mol Med. 24:13070–13080. 2020. View Article : Google Scholar : PubMed/NCBI

Yang M, Huang S, Zhao Y, Xie B, Hu X and Cai Y: Novel LncRNA AK023507 inhibits cell metastasis and proliferation in papillary thyroid cancer through β-catenin/Wnt signaling pathway. Biochem Biophys Res Commun. 655:104–109. 2023. View Article : Google Scholar : PubMed/NCBI

Zheng Z, Zhou X, Cai Y, Chen E, Zhang X, Wang O, Wang Q and Liu H: TEKT₄ promotes papillary thyroid cancer cell proliferation, colony formation, and metastasis through activating PI3K/Akt pathway. Endocr Pathol. 29:310–316. 2018. View Article : Google Scholar : PubMed/NCBI

Chen L, Zhuo D and Yuan H: Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway. Immunol Lett. 246:10–17. 2022. View Article : Google Scholar : PubMed/NCBI

Park JH, Myung JK, Lee SJ, Kim H, Kim S, Lee SB, Jang H, Jang WI, Park S, Yang H, et al: ABCA1-Mediated EMT promotes papillary thyroid cancer malignancy through the ERK/Fra-1/ZEB1 Pathway. Cells. 12:2742023. View Article : Google Scholar : PubMed/NCBI

He J, Zhou M, Yin J, Wan J, Chu J, Jia J, Sheng J, Wang C, Yin H and He F: METTL3 restrains papillary thyroid cancer progression via m⁶A/c-Rel/IL-8-mediated neutrophil infiltration. Mol Ther. 29:1821–1837. 2021. View Article : Google Scholar : PubMed/NCBI

Yang L, Tan Z, Li Y, Zhang X, Wu Y, Xu B and Wang M: Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the STAT3 pathway. J Clin Lab Anal. 34:e235312020. View Article : Google Scholar : PubMed/NCBI

Hong S, Xie Y, Cheng Z, Li J, He W, Guo Z, Zhang Q, Peng S, He M, Yu S, et al: Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability. Oncogene. 41:5121–5132. 2022. View Article : Google Scholar : PubMed/NCBI

Carnazza M, Quaranto D, DeSouza N, Moscatello AL, Garber D, Hemmerdinger S, Islam HK, Tiwari RK, Li XM and Geliebter J: The current understanding of the molecular pathogenesis of papillary thyroid cancer. Int J Mol Sci. 26:46462005. View Article : Google Scholar

Ju SH, Song M, Lim JY, Kang YE, Yi HS and Shong M: Metabolic reprogramming in thyroid cancer. Endocrinol Metab (Seoul). 39:425–444. 2024. View Article : Google Scholar : PubMed/NCBI

Huang J, Sun W, Wang Z, Lv C, Zhang T, Zhang D, Dong W, Shao L, He L, Ji X, et al: FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. J Exp Clin Cancer Res. 41:422022. View Article : Google Scholar : PubMed/NCBI

Strickaert A, Corbet C, Spinette SA, Craciun L, Dom G, Andry G, Larsimont D, Wattiez R, Dumont JE, Feron O, et al: Reprogramming of energy metabolism: Increased expression and roles of pyruvate carboxylase in papillary thyroid cancer. Thyroid. 29:845–857. 2019. View Article : Google Scholar : PubMed/NCBI

Xie W, Zeng Y, Hu L, Hao J, Chen Y, Yun X, Lin Q and Li H: Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy. Front Immunol. 13:9916562022. View Article : Google Scholar : PubMed/NCBI

Shen CT, Wei WJ, Qiu ZL, Song HJ, Zhang XY, Sun ZK and Luo QY: Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo. J Mol Endocrinol. 58:15–23. 2017. View Article : Google Scholar : PubMed/NCBI

Ren X, Shu J, Wang J, Guo Y, Zhang Y, Yue L, Yu H, Chen W, Zhang C, Ma J and Li Z: Machine learning reveals salivary glycopatterns as potential biomarkers for the diagnosis and prognosis of papillary thyroid cancer. Int J Biol Macromol. 215:280–289. 2022. View Article : Google Scholar : PubMed/NCBI

Wang Y, Yang L, Mao L, Zhang L, Zhu Y, Xu Y, Cheng Y, Sun R, Zhang Y, Ke J and Zhao D: SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Cancer Cell Int. 22:742022. View Article : Google Scholar : PubMed/NCBI

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, et al: Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin Cancer Res. 24:4030–4043. 2018. View Article : Google Scholar : PubMed/NCBI

Wen S, Luo Y, Wu W, Zhang T, Yang Y, Ji Q, Wu Y, Shi R, Ma B, Xu M and Qu N: Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer. Acta Biochim Biophys Sin (Shanghai). 53:1579–1589. 2021. View Article : Google Scholar : PubMed/NCBI

Xu M, Sun T, Wen S, Zhang T, Wang X, Cao Y, Wang Y, Sun X, Ji Q, Shi R and Qu N: Characteristics of lipid metabolism-related gene expression-based molecular subtype in papillary thyroid cancer. Acta Biochim Biophys Sin (Shanghai). 52:1166–1170. 2020. View Article : Google Scholar : PubMed/NCBI

Liao T, Wang YJ, Hu JQ, Wang Y, Han LT, Ma B, Shi RL, Qu N, Wei WJ, Guan Q, et al: Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro. Oncol Rep. 39:2185–2192. 2018.PubMed/NCBI

Zwara A, Hellmann A, Czapiewska M, Korczynska J, Sztendel A and Mika A: The influence of cancer on the reprogramming of lipid metabolism in healthy thyroid tissues of patients with papillary thyroid carcinoma. Endocrine. 87:273–280. 2024. View Article : Google Scholar : PubMed/NCBI

Abooshahab R, Hooshmand K, Razavi SA, Gholami M, Sanoie M and Hedayati M: Plasma metabolic profiling of human thyroid nodules by gas Chromatography-mass spectrometry (GC-MS)-based untargeted metabolomics. Front Cell Dev Biol. 8:3852020. View Article : Google Scholar : PubMed/NCBI

Ambrosi F, Righi A, Ricci C, Erickson LA, Lloyd RV and Asioli S: Hobnail variant of papillary thyroid carcinoma: A literature review. Endocr Pathol. 28:293–301. 2017. View Article : Google Scholar : PubMed/NCBI

Aprile M, Cataldi S, Perfetto C, Federico A, Ciccodicola A and Costa V: Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype. Br J Cancer. 129:249–265. 2023. View Article : Google Scholar : PubMed/NCBI

Badziong J, Ting S, Synoracki S, Tiedje V, Brix K, Brabant G, Moeller LC, Schmid KW, Fuhrer D and Zwanziger D: Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism. Eur J Endocrinol. 177:243–250. 2017. View Article : Google Scholar : PubMed/NCBI

Bai N, Xia F, Wang W, Lei Y, Bo J and Li X: CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway. J Cancer. 11:4308–4315. 2020. View Article : Google Scholar : PubMed/NCBI

Chen W, Fu J, Chen Y, Li Y, Ning L, Huang D, Yan S and Zhang Q: Circular RNA circKIF4A facilitates the malignant progression and suppresses ferroptosis by sponging miR-1231 and upregulating GPX4 in papillary thyroid cancer. Aging (Albany NY). 13:16500–16512. 2021. View Article : Google Scholar : PubMed/NCBI

Chen W, Zhang T, Bai Y, Deng H, Yang F, Zhu R, Chen Y, He Z, Zeng Q and Song M: Upregulated circRAD18 promotes tumor progression by reprogramming glucose metabolism in papillary thyroid cancer. Gland Surg. 10:2500–2510. 2021. View Article : Google Scholar : PubMed/NCBI

Chong ST, Tan KM, Kok CYL, Guan SP, Lai SH, Lim C, Hu J, Sturgis C, Eng C, Lam PYP, et al: IL13RA2 is differentially regulated in papillary thyroid carcinoma vs follicular thyroid carcinoma. J Clin Endocrinol Metab. 104:5573–5584. 2019. View Article : Google Scholar : PubMed/NCBI

Davis PJ, Lin HY, Hercbergs A and Mousa SA: Actions of L-thyroxine (T4) and tetraiodothyroacetic acid (Tetrac) on gene expression in thyroid cancer cells. Genes (Basel). 11:7552020. View Article : Google Scholar : PubMed/NCBI

Fan X and Zhao Y: miR-451a inhibits cancer growth, epithelial-mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8. J Cell Mol Med. 23:8067–8075. 2019. View Article : Google Scholar : PubMed/NCBI

Feng Z, Song Y, Qian J, Chen T, Yang C, Jia L, Liu C, Liu P, Lv J and Deng Z: Differential expression of a set of microRNA genes reveals the potential mechanism of papillary thyroid carcinoma. Ann Endocrinol (Paris). 80:77–83. 2019. View Article : Google Scholar : PubMed/NCBI

Gunjača I, Benzon B, Pleić N, Babić Leko M, Pešutić Pisac V, Barić A, Kaličanin D, Punda A, Polašek O, Vukojević K, et al: Role of ST6GAL1 in thyroid cancers: Insights from tissue analysis and genomic datasets. Int J Mol Sci. 24:163342023. View Article : Google Scholar : PubMed/NCBI

Ha TK, Jung I, Kim ME, Bae SK and Lee JS: Anti-cancer activity of myricetin against human papillary thyroid cancer cells involves mitochondrial Dysfunction-mediated apoptosis. Biomed Pharmacother. 91:378–384. 2017. View Article : Google Scholar : PubMed/NCBI

Hińcza K, Kowalik A, Pałyga I, Walczyk A, Gąsior-Perczak D, Mikina E, Trybek T, Szymonek M, Gadawska-Juszczyk K, Zajkowska K, et al: Does the TT variant of the rs966423 polymorphism in DIRC3 affect the stage and clinical course of papillary thyroid cancer? Cancers (Basel). 12:4232020. View Article : Google Scholar : PubMed/NCBI

Hu H, Quan G, Yang F, Du S, Ding S, Lun Y and Chen Q: MicroRNA-96-5p is negatively regulating GPC3 in the metastasis of papillary thyroid cancer. SAGE Open Med. 11:205031212312057102023. View Article : Google Scholar : PubMed/NCBI

Hu Z, Zhao P, Zhang K, Zang L, Liao H and Ma W: Hsa_circ_0011290 regulates proliferation, apoptosis and glycolytic phenotype in papillary thyroid cancer via miR-1252/ FSTL1 signal pathway. Arch Biochem Biophys. 685:1083532020. View Article : Google Scholar : PubMed/NCBI

Jeon MJ, You MH, Han JM, Sim S, Yoo HJ, Lee WK, Kim TY, Song DE, Shong YK, Kim WG and Kim WB: High phosphoglycerate dehydrogenase expression induces stemness and aggressiveness in thyroid cancer. Thyroid. 30:1625–1638. 2020. View Article : Google Scholar : PubMed/NCBI

Jin L, Zheng D, Mo D, Guan Y, Wen J, Zhang X and Chen C: Glucose-to-Lymphocyte ratio (GLR) as a predictor of preoperative central lymph node metastasis in papillary thyroid cancer patients with type 2 diabetes mellitus and construction of the nomogram. Front Endocrinol (Lausanne). 13:8290092022. View Article : Google Scholar : PubMed/NCBI

Kang YE, Kim JT, Lim MA, Oh C, Liu L, Jung SN, Won HR, Lee K, Chang JW, Yi HS, et al: Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. Cancers (Basel). 11:11542019. View Article : Google Scholar : PubMed/NCBI

Li X, Wu Z, He J, Jin Y, Chu C, Cao Y, Gu F, Wang H, Hou C, Liu X and Zou Q: OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP. Oncogene. 40:4859–4871. 2021. View Article : Google Scholar : PubMed/NCBI

Li Y, Chen M, Liu C, Xia Y, Xu B, Hu Y, Chen T, Shen M and Tang W: Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study. Int J Mol Med. 41:3006–3014. 2018.PubMed/NCBI

Lu J, Zhang Y, Sun M, Ding C, Zhang L, Kong Y, Cai M, Miccoli P, Ma C and Yue X: Multi-omics analysis of fatty acid metabolism in thyroid carcinoma. Front Oncol. 11:7371272021. View Article : Google Scholar : PubMed/NCBI

Mardente S, Romeo MA, Asquino A, Po A, Gilardini Montani MS and Cirone M: HHV-6A infection of papillary thyroid cancer cells induces several effects related to cancer progression. Viruses. 15:21222023. View Article : Google Scholar : PubMed/NCBI

Nahm JH, Kim HM and Koo JS: Glycolysis-related protein expression in thyroid cancer. Tumour Biol. 39:10104283176959222017. View Article : Google Scholar : PubMed/NCBI

Nilsson JN, Siikanen J, Hedman C, Juhlin CC and Ihre Lundgren C: Pre-Therapeutic measurements of iodine avidity in papillary and poorly differentiated thyroid cancer reveal associations with thyroglobulin expression, histological variants and Ki-67 index. Cancers (Basel). 13:36272021. View Article : Google Scholar : PubMed/NCBI

Parascandolo A, Rappa F, Cappello F, Kim J, Cantu DA, Chen H, Mazzoccoli G, Hematti P, Castellone MD, Salvatore M and Laukkanen MO: Extracellular superoxide dismutase expression in papillary thyroid cancer mesenchymal Stem/Stromal cells modulates cancer cell growth and migration. Sci Rep. 7:414162017. View Article : Google Scholar : PubMed/NCBI

Piana S, Zanetti E, Bisagni A, Ciarrocchi A, Giordano D, Torricelli F, Rossi T and Ragazzi M: Expression of NOTCH1 in thyroid cancer is mostly restricted to papillary carcinoma. Endocr Connect. 8:1089–1096. 2019. View Article : Google Scholar : PubMed/NCBI

Sekhar KR, Cyr S and Baregamian N: Ferroptosis inducers in thyroid cancer. World J Surg. 47:371–381. 2023. View Article : Google Scholar : PubMed/NCBI

Song H, Qiu Z, Wang Y, Xi C, Zhang G, Sun Z, Luo Q and Shen C: HIF-1α/YAP signaling rewrites Glucose/Iodine metabolism program to promote papillary thyroid cancer progression. Int J Biol Sci. 19:225–241. 2023. View Article : Google Scholar : PubMed/NCBI

Sun Y, Gong J, Guo B, Shang J, Cheng Y and Xu H: Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer. Oral Oncol. 87:152–157. 2018. View Article : Google Scholar : PubMed/NCBI

Valvo V, Iesato A, Kavanagh TR, Priolo C, Zsengeller Z, Pontecorvi A, Stillman IE, Burke SD, Liu X and Nucera C: Fine-tuning lipid metabolism by targeting Mitochondria-associated Ac92etyl-CoA-Carboxylase 2 in BRAF(V600E) papillary thyroid carcinoma. Thyroid. 31:1335–1358. 2021. View Article : Google Scholar : PubMed/NCBI

Wu C, Ma L, Wei H, Nie F, Ning J and Jiang T: MiR-1256 inhibits cell proliferation and cell cycle progression in papillary thyroid cancer by targeting 5-hydroxy tryptamine receptor 3A. Hum Cell. 33:630–640. 2020. View Article : Google Scholar : PubMed/NCBI

Xia M, Wang S, Wang L, Mei Y, Tu Y and Gao L: The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer. Front Endocrinol (Lausanne). 14:10623172023. View Article : Google Scholar : PubMed/NCBI

Xu K and Feng Y: HOXD-AS1 is a predictor of clinical progression and functions as an oncogenic lncRNAs in papillary thyroid cancer. J Cell Biochem. 120:5326–5332. 2019. View Article : Google Scholar : PubMed/NCBI

Yun HJ, Kim M, Kim SY, Fang S, Kim Y, Chang HS, Chang HJ and Park KC: Effects of Anti-cancer drug Sensitivity-related genetic differences on therapeutic approaches in refractory papillary thyroid cancer. Int J Mol Sci. 23:6992022. View Article : Google Scholar : PubMed/NCBI

Zarkesh M, Zadeh-Vakili A, Akbarzadeh M, Fanaei SA, Hedayati M and Azizi F: The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer. BMC Cancer. 18:11992018. View Article : Google Scholar : PubMed/NCBI

Zeng J, Ma X, Wang J, Liu R, Shao Y, Hou Y, Li Z and Fang Y: Down-regulated HSDL2 expression suppresses cell proliferation and promotes apoptosis in papillary thyroid carcinoma. Biosci Rep. 39:BSR201904252019. View Article : Google Scholar : PubMed/NCBI

Zhang C, Bo C, Guo L, Yu P, Miao S and Gu X: BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis. World J Surg Oncol. 17:2212019. View Article : Google Scholar : PubMed/NCBI

Zhang J, Wen X, Li Y, Zhang J, Li X, Qian C, Tian Y, Ling R and Duan Y: Diagnostic approach to thyroid cancer based on amino acid metabolomics in saliva by ultra-performance liquid chromatography with high resolution mass spectrometry. Talanta. 235:1227292021. View Article : Google Scholar : PubMed/NCBI

Zhao F, Zhu S, Fang J, Dong H and Zhu C: Correlation of DNA methylation and lymph node metastasis in papillary thyroid carcinoma. Head Neck. 45:1654–1662. 2023. View Article : Google Scholar : PubMed/NCBI

Sengun S, Korkmaz H, Ciris M, Yüceer RO, Boyluboy SM and Kiran M: Diagnostic and prognostic value of Stanniocalcin 1 expression in papillary thyroid cancer. Endocrine. 78:95–103. 2022. View Article : Google Scholar : PubMed/NCBI

Luo JH, Zhang XX and Sun WH: F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer. Aging (Albany NY). 14:3687–3704. 2022. View Article : Google Scholar : PubMed/NCBI

Zhang K, Li C, Liu J, Li Z and Ma C: Down-regulation of APTR and it's diagnostic value in papillary and anaplastic thyroid cancer. Pathol Oncol Res. 26:559–565. 2020. View Article : Google Scholar : PubMed/NCBI

Bumber B, Marjanovic Kavanagh M, Jakovcevic A, Sincic N, Prstacic R and Prgomet D: Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer. Clin Otolaryngol. 45:55–62. 2020. View Article : Google Scholar : PubMed/NCBI

Ali KM, Awny S, Ibrahim DA, Metwally IH, Hamdy O, Refky B, Abdallah A and Abdelwahab K: Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer. Ann Diagn Pathol. 40:59–65. 2019. View Article : Google Scholar : PubMed/NCBI

Wang Y, Song W, Li Y, Liu Z, Zhao K, Jia L, Wang X, Jiang R, Tian Y and He X: Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology. J Cancer Res Clin Oncol. 149:16837–16850. 2023. View Article : Google Scholar : PubMed/NCBI

Boucai L, Zafereo M and Cabanillas ME: Thyroid cancer: A review. JAMA. 331:425–435. 2024. View Article : Google Scholar : PubMed/NCBI

Levine RA: History of thyroid ultrasound. Thyroid. 33:894–902. 2023. View Article : Google Scholar : PubMed/NCBI

Mitchell AL, Gandhi A, Scott-Coombes D and Perros P: Management of thyroid cancer: United kingdom national multidisciplinary guidelines. J Laryngol Otol. 130 (Suppl):S150–S160. 2016. View Article : Google Scholar : PubMed/NCBI

Hou ZK, Zhao J, Zhang M, Hou W, Li Y, Yang Y, Liu Y, Ye Z, Cai Q, Wei X, et al: Preoperative identification of papillary thyroid carcinoma subtypes and lymph node metastasis via deep Learning-Assisted Surface-enhanced raman spectroscopy. ACS Nano. 19:21807–21819. 2025. View Article : Google Scholar : PubMed/NCBI

Su X, Shang L, Yue C and Ma B: Ultrasound-guided fine needle aspiration thyroglobulin in the diagnosis of lymph node metastasis of differentiated papillary thyroid carcinoma and its influencing factors. Front Endocrinol (Lausanne). 15:13048322024. View Article : Google Scholar : PubMed/NCBI

Zhao L, Zhang X and Cui S: Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway. Oncol Lett. 16:2965–2970. 2018.PubMed/NCBI

Fu S, Ma C, Tang X, Ma X, Jing G, Zhao N and Ran J: MiR-192-5p inhibits proliferation, migration, and invasion in papillary thyroid carcinoma cells by regulation of SH3RF3. Biosci Rep. 41:BSR202103422021. View Article : Google Scholar : PubMed/NCBI

Fu S, Zhao N, Jing G, Yang X, Liu J, Zhen D and Tang X: Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p. Biomed Pharmacother. 128:1103272020. View Article : Google Scholar : PubMed/NCBI

Wen SS, Wu YJ, Wang JY, Ni ZX, Dong S, Xie XJ, Wang YT, Wang Y, Huang NS, Ji QH, et al: BRAFV600E/p-ERK/p-DRP1(Ser616) promotes tumor progression and reprogramming of glucose metabolism in papillary thyroid cancer. Thyroid. 34:1246–1259. 2024. View Article : Google Scholar : PubMed/NCBI

Liu B, Peng Y, Su Y, Diao C, Cha L and Cheng R: Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer. Discov Oncol. 16:10822025. View Article : Google Scholar : PubMed/NCBI

Limberg J, Egan CE, Gray KD, Singh M, Loewenstein Z, Yang Y, Riascos MC, Al Asadi H, Safe P, El Eshaky S, et al: Activation of the JAK/STAT pathway leads to BRAF inhibitor resistance in BRAFV600E positive thyroid carcinoma. Mol Cancer Res. 21:397–410. 2023. View Article : Google Scholar : PubMed/NCBI

Sui F, Wang G, Liu J, Yuan M, Chen P, Yao Y, Zhang S, Ji M and Hou P: Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors. Cell Mol Life Sci. 81:2382024. View Article : Google Scholar : PubMed/NCBI

Xu M, Zhao D, Chen Y, Chen C, Zhang L, Sun L, Chen J, Tang Q, Sun S, Ma C, et al: Charge reversal polypyrrole nanocomplex-mediated gene delivery and photothermal therapy for effectively treating papillary thyroid cancer and inhibiting lymphatic metastasis. ACS Appl Mater Interfaces. 14:14072–14086. 2022. View Article : Google Scholar : PubMed/NCBI

Pearce EN and Caldwell KL: Urinary iodine, thyroid function, and thyroglobulin as biomarkers of iodine status. AmJ Clin Nutr. 104 (Suppl 3):898S–901S. 2016. View Article : Google Scholar : PubMed/NCBI

Sørensen SM, de la Cour CD, Maltesen T, Urbute A and Kjaer SK: Temporal trends in papillary and follicular thyroid cancer incidence from 1995 to 2019 in adults in denmark according to education and income. Thyroid. 32:972–982. 2022. View Article : Google Scholar : PubMed/NCBI

Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E and Devesa SS: Follicular thyroid cancer incidence patterns in the United states 1980–2009. Thyroid. 23:1015–1021. 2013. View Article : Google Scholar : PubMed/NCBI

Kitahara CM and Sosa JA: The changing incidence of thyroid cancer. Nat Rev Endocrinol. 12:646–653. 2016. View Article : Google Scholar : PubMed/NCBI

Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P and Grogan RH: The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol. 20:2746–2753. 2013. View Article : Google Scholar : PubMed/NCBI

Liu LP, Hao JY, Pan H, Wang C and Yue P: Mutation of RAS gene in follicular-differentiated thyroid tumors and its significance. Zhonghua Bing Li Xue Za Zhi. 49:256–261. 2020.(In Chinese). PubMed/NCBI

Yang X and Wu H: RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 17:1082024. View Article : Google Scholar : PubMed/NCBI

Tartaglia M and Gelb BD: Disorders of dysregulated signal traffic through the RAS-MAPK pathway: Phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci. 1214:99–121. 2010. View Article : Google Scholar : PubMed/NCBI

Bahar ME, Kim HJ and Kim DR: Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies. Signal Transduct Target Ther. 8:4552023. View Article : Google Scholar : PubMed/NCBI

Takács T, Kudlik G, Kurilla A, Szeder B, Buday L and Vas V: The effects of mutant Ras proteins on the cell signalome. Cancer Metastasis Rev. 39:1051–1065. 2020. View Article : Google Scholar : PubMed/NCBI

De Martino M, Esposito F, Capone M, Pallante P and Fusco A: Noncoding RNAs in thyroid-follicular-cell-derived carcinomas. Cancers (Basel). 14:30792022. View Article : Google Scholar : PubMed/NCBI

Srinivasan V, Asghar MY, Zafar S, Törnquist K and Lindholm D: Proliferation and migration of ML1 follicular thyroid cancer cells are inhibited by IU1 targeting USP14: Role of proteasome and autophagy flux. Front Cell Dev Biol. 11:12342042023. View Article : Google Scholar : PubMed/NCBI

Lin TH, Kuo CH, Zhang YS, Chen PT, Chen SH, Li YZ and Lee YR: Piperlongumine induces cellular apoptosis and autophagy via the ROS/Akt signaling pathway in human follicular thyroid cancer cells. Int J Mol Sci. 24:80482023. View Article : Google Scholar : PubMed/NCBI

Pribyl M, Hodny Z and Kubikova I: Suprabasin-A review. Genes (Basel). 108:122021.

Tan H, Wang L and Liu Z: Role of suprabasin in the dedifferentiation of follicular epithelial Cell-derived thyroid cancer and identification of related immune markers. Front Genet. 13:8106812022. View Article : Google Scholar : PubMed/NCBI

Iesato A, Nakamura T, Izumi H, Uehara T and Ito KI: PATZ1 knockdown enhances malignant phenotype in thyroid epithelial follicular cells and thyroid cancer cells. Oncotarget. 8:82754–82772. 2017. View Article : Google Scholar : PubMed/NCBI

Yoshida J, Iwabuchi K, Matsui T, Ishibashi T, Masuoka T and Nishio M: Knockdown of stromal interaction molecule 1 (STIM1) suppresses store-operated calcium entry, cell proliferation and tumorigenicity in human epidermoid carcinoma A431 cells. Biochem Pharmacol. 84:1592–1603. 2012. View Article : Google Scholar : PubMed/NCBI

Kuang CY, Yu Y, Guo RW, Qian DH, Wang K, Den MY, Shi YK and Huang L: Silencing stromal interaction molecule 1 by RNA interference inhibits the proliferation and migration of endothelial progenitor cells. Biochem Biophys Res Commun. 398:315–320. 2010. View Article : Google Scholar : PubMed/NCBI

Asghar MY, Lassila T, Paatero I, Nguyen VD, Kronqvist P, Zhang J, Slita A, Löf C, Zhou Y, Rosenholm J and Törnquist K: Stromal interaction molecule 1 (STIM1) knock down attenuates invasion and proliferation and enhances the expression of Thyroid-specific proteins in human follicular thyroid cancer cells. Cell Mol Life Sci. 78:5827–5846. 2021. View Article : Google Scholar : PubMed/NCBI

Cai X, Sun R, Yang L, Yao N, Sun Y, Zhang G, Ge W, Zhou Y, Gui Z, Wang Y, et al: Proteomic analysis reveals modulation of key proteins in follicular thyroid cancer progression. Chin Med J (Engl). May 21;doi: 10.1097/CM9.0000000000003645 (Epub ahead of print).

Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, Gangadaran P and Ahn BC: Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun (Lond). 43:525–561. 2023. View Article : Google Scholar : PubMed/NCBI

Rudzińska M, Mikula M, Arczewska KD, Gajda E, Sabalińska S, Stępień T, Ostrowski J and Czarnocka B: Transcription factor prospero Homeobox 1 (PROX1) as a potential angiogenic regulator of follicular thyroid cancer dissemination. Int J Mol Sci. 20:56192019. View Article : Google Scholar : PubMed/NCBI

Li Q, Liu W, Wang Z, Wang C and Ai Z: Exosomal ANXA1 derived from thyroid cancer cells is associated with malignant transformation of human thyroid follicular epithelial cells by promoting cell proliferation. Int J Oncol. 59:1042021. View Article : Google Scholar : PubMed/NCBI

Zhou Q, Chen J, Feng J, Xu Y, Zheng W and Wang J: SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways. Mol Cell Biochem. 435:87–95. 2017. View Article : Google Scholar : PubMed/NCBI

Fuziwara CS, Saito KC, Leoni SG, Waitzberg  FL and Kimura ET: The highly expressed FAM83F protein in papillary thyroid cancer exerts a Pro-oncogenic role in thyroid follicular cells. Front Endocrinol (Lausanne). 10:1342019. View Article : Google Scholar : PubMed/NCBI

Xu G, Chen J, Wang G, Xiao J, Zhang N, Chen Y, Yu H, Wang G and Zhao Y: Resveratrol inhibits the tumorigenesis of follicular thyroid cancer via ST6GAL2-Regulated activation of the hippo signaling pathway. Mol Ther Oncolytics. 16:124–133. 2020. View Article : Google Scholar : PubMed/NCBI

Campisi A, Bonfanti R, Raciti G, Bonaventura G, Legnani L, Magro G, Pennisi M, Russo G, Chiacchio MA, Pappalardo F and Parenti R: Gene silencing of Transferrin-1 receptor as a potential therapeutic target for human follicular and anaplastic thyroid cancer. Mol Ther Oncolytics. 16:197–206. 2020. View Article : Google Scholar : PubMed/NCBI

Bai F, Liu X, Zhang X, Mao Z, Wen H, Ma J and Pei XH: p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer. Cell Cycle. 22:1637–1653. 2023. View Article : Google Scholar : PubMed/NCBI

Erinjeri NJ, Nicolson NG, Deyholos C, Korah R and Carling T: Whole-exome sequencing identifies two discrete druggable signaling pathways in follicular thyroid cancer. J Am Coll Surg. 226:950–959.e5. 2018. View Article : Google Scholar : PubMed/NCBI

Fozzatti L, Alamino VA, Park S, Giusiano L, Volpini X, Zhao L, Stempin CC, Donadio AC, Cheng SY and Pellizas CG: Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression. Sci Rep. 9:80282019. View Article : Google Scholar : PubMed/NCBI

Xu PP, Zeng S, Xia XT, Ye ZH, Li MF, Chen MY, Xia T, Xu JJ, Jiao Q, Liu L, et al: 2020: FAM172A promotes follicular thyroid carcinogenesis and may be a marker of FTC. Endocr Relat Cancer. 27:657–669. 2020. View Article : Google Scholar : PubMed/NCBI

Liu JL, Mao Z, Gallick GE and Yung WK: AMPK/ TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol. 13:184–194. 2011. View Article : Google Scholar : PubMed/NCBI

Pringle DR, Vasko VV, Yu L, Manchanda PK, Lee AA, Zhang X, Kirschner JM, Parlow AF, Saji M, Jarjoura D, et al: Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. J Clin Endocrinol Metab. 99:E804–E812. 2014. View Article : Google Scholar : PubMed/NCBI

Kari S, Vasko VV, Priya S and Kirschner LS: PKA activates AMPK through LKB1 signaling in follicular thyroid cancer. Front Endocrinol (Lausanne). 10:7692019. View Article : Google Scholar : PubMed/NCBI

Borowczyk M, Szczepanek-Parulska E, Dębicki S, Budny B, Janicka-Jedyńska M, Gil L, Verburg FA, Filipowicz D, Wrotkowska E, Majchrzycka B, et al: High incidence of FLT3 mutations in follicular thyroid cancer: Potential therapeutic target in patients with advanced disease stage. Ther Adv Med Oncol. 12:17588359209075342020. View Article : Google Scholar : PubMed/NCBI

Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, Do Cao C, Leboulleux S, Klein M, Tabarin A, et al: Effect of buparlisib, a Pan-class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer. Thyroid. 28:1174–1179. 2018. View Article : Google Scholar : PubMed/NCBI

El-Azem N, Pulido-Moran M, Ramirez-Tortosa CL, Quiles JL, Cara FE, Sanchez-Rovira P, Granados-Principal S and Ramirez-Tortosa M: Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer. Eur J Nutr. 58:1203–1211. 2019. View Article : Google Scholar : PubMed/NCBI

Toteda G, Lupinacci S, Vizza D, Bonofiglio R, Perri E, Bonofiglio M, Lofaro D, La Russa A, Leone F, Gigliotti P, et al: High doses of hydroxytyrosol induce apoptosis in papillary and follicular thyroid cancer cells. J Endocrinol Invest. 40:153–162. 2017. View Article : Google Scholar : PubMed/NCBI

Son Y, Lee JH, Chung HT and Pae HO: Therapeutic roles of heme oxygenase-1 in metabolic diseases: Curcumin and resveratrol analogues as possible inducers of heme oxygenase-1. Oxid Med Cell Longev. 2013:6395412013. View Article : Google Scholar : PubMed/NCBI

Li R, Zhang J, Zhou Y, Gao Q, Wang R, Fu Y, Zheng L and Yu H: Transcriptome investigation and in vitro verification of Curcumin-induced HO-1 as a feature of ferroptosis in breast cancer cells. Oxid Med Cell Longev. 2020:34698402020. View Article : Google Scholar : PubMed/NCBI

Kwon MY, Park E, Lee SJ and Chung SW: Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 6:24393–24403. 2015. View Article : Google Scholar : PubMed/NCBI

Chen H, Li Z, Xu J, Zhang N, Chen J, Wang G and Zhao Y: Curcumin induces ferroptosis in follicular thyroid cancer by upregulating HO-1 expression. Oxid Med Cell Longev. 2023:68967902023. View Article : Google Scholar : PubMed/NCBI

Li Q, Zhang S, Wang M, Dong S, Wang Y, Liu S, Lu T, Fu Y, Wang X and Chen G: Downregulated miR-21 mediates matrine-induced apoptosis via the PTEN/Akt signaling pathway in FTC-133 human follicular thyroid cancer cells. Oncol Lett. 18:3553–3560. 2019.PubMed/NCBI

Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, et al: Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. Endocrine. 49:854–858. 2015. View Article : Google Scholar : PubMed/NCBI

Sousa Santos F, Joana Santos R and Leite V: Sorafenib and sunitinib for the treatment of metastatic thyroid cancer of follicular origin: A 7-year Single-Centre experience. Eur Thyroid J. 8:262–267. 2019. View Article : Google Scholar : PubMed/NCBI

Lan L, Basourakos S, Cui D, Zuo X, Deng W, Huo L, Chen L, Zhang G, Deng L, Shi B, et al: Inhibiting β-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization. Oncol Rep. 37:426–434. 2017. View Article : Google Scholar : PubMed/NCBI

Dias D, Damásio I, Marques P, Simões H, Rodrigues R, Cavaco BM and Leite V: Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin. Eur Thyroid J. 12:e2202272023. View Article : Google Scholar : PubMed/NCBI

Heffess CS and Thompson LD: Minimally invasive follicular thyroid carcinoma. Endocr Pathol. 12:417–422. 2001. View Article : Google Scholar : PubMed/NCBI

Hernandez-Prera JC and Wenig BM: RAS-mutant follicular thyroid tumors: A continuous challenge for pathologists. Endocr Pathol. 35:167–184. 2024. View Article : Google Scholar : PubMed/NCBI

Lang BH, Lo CY, Chan WF, Lam KY and Wan KY: Prognostic factors in papillary and follicular thyroid carcinoma: Their implications for cancer staging. Ann Surg Oncol. 14:730–738. 2007. View Article : Google Scholar : PubMed/NCBI

Levi J, Kothapalli SR, Bohndiek S, Yoon JK, Dragulescu-Andrasi A, Nielsen C, Tisma A, Bodapati S, Gowrishankar G, Yan X, et al: Molecular photoacoustic imaging of follicular thyroid carcinoma. Clin Cancer Res. 19:1494–1502. 2013. View Article : Google Scholar : PubMed/NCBI

Li G, Wang H, Zhong J, Bai Y, Chen W, Jiang K, Huang J, Shao Y, Liu J, Gong Y, et al: Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: A diagnostic study. Br J Cancer. 130:925–933. 2024. View Article : Google Scholar : PubMed/NCBI

Liang L, Xu J, Wang M, Xu G, Zhang N, Wang G and Zhao Y: LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. Cell Death Dis. 9:3722018. View Article : Google Scholar : PubMed/NCBI

Lin J, Qiu Y, Zheng X, Dai Y and Xu T: The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma. BMC Cancer. 22:7562022. View Article : Google Scholar : PubMed/NCBI

Lo CY, Chan WF, Lam KY and Wan KY: Follicular thyroid carcinoma: The role of histology and staging systems in predicting survival. Ann Surg. 242:708–715. 2005. View Article : Google Scholar : PubMed/NCBI

Macerola E, Proietti A, Poma AM, Vignali P, Sparavelli R, Ginori A, Basolo A, Elisei R, Santini F and Basolo F: Limited accuracy of Pan-trk immunohistochemistry screening for NTRK rearrangements in Follicular-derived thyroid carcinoma. Int J Mol Sci. 23:74702022. View Article : Google Scholar : PubMed/NCBI

Park H, Shin HC, Yang H, Heo J, Ki CS, Kim HS, Kim JH, Hahn SY, Chung YJ, Kim SW, et al: Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. Mod Pathol. 35:186–192. 2022. View Article : Google Scholar : PubMed/NCBI

Paulsson JO, Wang N, Gao J, Stenman A, Zedenius J, Mu N, Lui WO, Larsson C and Juhlin CC: GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours. Endocr Relat Cancer. 27:295–308. 2020. View Article : Google Scholar : PubMed/NCBI

Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F and Schlumberger M: Poorly differentiated follicular thyroid carcinoma: Prognostic factors and relevance of histological classification. Thyroid. 17:639–646. 2007. View Article : Google Scholar : PubMed/NCBI

Repaci A, Salituro N, Vicennati V, Monari F, Cavicchi O, de Biase D, Ciarrocchi A, Acquaviva G, De Leo A, Gruppioni E, et al: Unexpected widespread bone metastases from a BRAF K601N mutated follicular thyroid carcinoma within a previously resected multinodular goiter. Endocr Pathol. 33:519–524. 2022. View Article : Google Scholar : PubMed/NCBI

Romitti M, Ceolin L, Siqueira DR, Ferreira CV, Wajner SM and Maia AL: Signaling pathways in follicular cell-derived thyroid carcinomas (review). Int J Oncol. 42:19–28. 2013. View Article : Google Scholar : PubMed/NCBI

Rossing M, Borup R, Henao R, Winther O, Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sørensen C, et al: Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. J Mol Endocrinol. 48:11–23. 2012. View Article : Google Scholar : PubMed/NCBI

Saburi S, Tsujikawa T, Miyagawa-Hayashino A, Mitsuda J, Yoshimura K, Kimura A, Morimoto H, Ohmura G, Arai A, Ogi H, et al: Spatially resolved immune microenvironmental profiling for follicular thyroid carcinoma with minimal capsular invasion. Mod Pathol. 35:721–727. 2022. View Article : Google Scholar : PubMed/NCBI

Staubitz JI, Musholt PB and Musholt TJ: The surgical dilemma of primary surgery for follicular thyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 33:1012922019. View Article : Google Scholar : PubMed/NCBI

Stenman A, Hysek M, Jatta K, Bränström R, Darai-Ramqvist E, Paulsson JO, Wang N, Larsson C, Zedenius J and Juhlin CC: TERT promoter mutation spatial heterogeneity in a metastatic follicular thyroid carcinoma: Implications for clinical work-up. Endocr Pathol. 30:246–248. 2019. View Article : Google Scholar : PubMed/NCBI

Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, et al: Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med. 129:622–627. 1998. View Article : Google Scholar : PubMed/NCBI

Thompson LDR: High grade differentiated follicular Cell-derived thyroid carcinoma versus poorly differentiated thyroid carcinoma: A clinicopathologic analysis of 41 cases. Endocr Pathol. 34:234–246. 2023. View Article : Google Scholar : PubMed/NCBI

Wenter V, Albert NL, Unterrainer M, Ahmaddy F, Ilhan H, Jellinek A, Knösel T, Bartenstein P, Spitzweg C, Lehner S, et al: Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging. 48:449–460. 2021. View Article : Google Scholar : PubMed/NCBI

Yu B, Li Y, Yu X, Ai Y, Jin J, Zhang J, Zhang Y, Zhu H, Xie C, Shen M, et al: Differentiate thyroid follicular adenoma from carcinoma with combined ultrasound radiomics features and clinical ultrasound features. J Digit Imaging. 35:1362–1372. 2022. View Article : Google Scholar : PubMed/NCBI

Zhang H, Zhang Z, Liu X, Duan H, Xiang T, He Q, Su Z, Wu H and Liang Z: DNA methylation haplotype block markers efficiently discriminate follicular thyroid carcinoma from follicular adenoma. J Clin Endocrinol Metab. 106:1011–1021. 2021. View Article : Google Scholar : PubMed/NCBI

Saltiki K, Simeakis G, Karapanou O and Alevizaki M: Management of Endocrine Disease: Medullary thyroid cancer: From molecular biology and therapeutic pitfalls to future targeted treatment perspectives. Eur J Endocrinol. 187:R53–R63. 2022. View Article : Google Scholar : PubMed/NCBI

Shi X, Sun Y, Shen C, Zhang Y, Shi R, Zhang F, Liao T, Lv G, Zhu Z, Jiao L, et al: Integrated proteogenomic characterization of medullary thyroid carcinoma. Cell Discov. 8:1202022. View Article : Google Scholar : PubMed/NCBI

Khan E, Hylton H, Rajan N, Bouley SJ, Siddiqui JK, Rajasekaran S, Koshre GR, Storts H, Valenciaga A, Khan M, et al: Proteomic profiling of medullary thyroid cancer identifies CAPN1 as a key regulator of NF1 and RET fueled growth. Thyroid. 35:177–187. 2025. View Article : Google Scholar : PubMed/NCBI

Navas-Carrillo D, Rodriguez JM, Montoro-García S and Orenes-Piñero E: High-resolution proteomics and metabolomics in thyroid cancer: Deciphering novel biomarkers. Crit Rev Clin Lab Sci. 54:446–457. 2017. View Article : Google Scholar : PubMed/NCBI

Khatami F and Tavangar SM: Genetic and epigenetic of medullary thyroid cancer. Iran Biomed J. 22:142–150. 2018.PubMed/NCBI

Rabold K, Zoodsma M, Grondman I, Kuijpers Y, Bremmers M, Jaeger M, Zhang B, Hobo W, Bonenkamp HJ, de Wilt JHW, et al: Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat Commun. 13:61492022. View Article : Google Scholar : PubMed/NCBI

Bi Y, Ren X, Bai X, Meng Y, Luo Y, Cao J, Zhang Y and Liang Z: PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population. Eur J Surg Oncol. 45:353–358. 2019. View Article : Google Scholar : PubMed/NCBI

Nikas IP, Kazamias G, Vrontaki M, Rapti AS and Mastorakis E: Medullary thyroid carcinoma diagnosed with liquid-based cytology and immunocytochemistry. J Immunoassay Immunochem. 43:502–515. 2022. View Article : Google Scholar : PubMed/NCBI

Besharat ZM, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C, Sabato C, Noviello TMR, Po A, Citarella A, et al: Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients. J Endocrinol Invest. 46:2583–2599. 2023. View Article : Google Scholar : PubMed/NCBI

Fugazzola L: Medullary thyroid cancer-An update. Best Pract Res Clin Endocrinol Metab. 37:1016552023. View Article : Google Scholar : PubMed/NCBI

Almeida MQ and Hoff AO: Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol. 24:229–234. 2012. View Article : Google Scholar : PubMed/NCBI

Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H and Croce CM: Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 9:2012024. View Article : Google Scholar : PubMed/NCBI

Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, Jiang Y, Liu Q and Xiong H: Kinase inhibitors and Kinase-targeted cancer therapies: Recent advances and future perspectives. Int J Mol Sci. 25:54892024. View Article : Google Scholar : PubMed/NCBI

Patel J, Klopper J and Cottrill EE: Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities. Front Endocrinol (Lausanne). 14:11014102023. View Article : Google Scholar : PubMed/NCBI

Giardino E, Catalano R, Mangili F, Barbieri AM, Treppiedi D, Elli FM, Dolci A, Contarino A, Spada A, Arosio M, et al: Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. Mol Cell Endocrinol. 520:1110922021. View Article : Google Scholar : PubMed/NCBI

Bareli Y, Shimon I, Tobar A and Rubinfeld H: PICT-1 regulates p53 splicing and sensitivity of medullary thyroid carcinoma cells to everolimus. J Neuroendocrinol. 34:e131872022. View Article : Google Scholar : PubMed/NCBI

Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, Meyer D, Guo A, Gundara J, Mettlach G, et al: The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 24:499–511. 2013. View Article : Google Scholar : PubMed/NCBI

Hedayati M, Zarif Yeganeh M, Sheikholeslami S and Afsari F: Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer. Crit Rev Clin Lab Sci. 53:217–227. 2016. View Article : Google Scholar : PubMed/NCBI

Yue CH, Oner M, Chiu CY, Chen MC, Teng CL, Wang HY, Hsieh JT, Lai CH and Lin H: RET regulates human medullary thyroid cancer cell proliferation through CDK5 and STAT3 Activation. Biomolecules. 11:8602021. View Article : Google Scholar : PubMed/NCBI

Kunte SC, Wenter V, Toms J, Lindner S, Unterrainer M, Eilsberger F, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, et al: PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [¹⁸F]SiTATE-first clinical experiences. Eur J Nucl Med Mol Imaging. 52:900–912. 2025. View Article : Google Scholar : PubMed/NCBI

Kong Z, Li Z, Cui XY, Wang J, Xu M, Liu Y, Chen J, Ni S, Zhang Z, Fan X, et al: CTR-FAPI PET enables precision management of medullary thyroid carcinoma. Cancer Discov. 15:316–328. 2025. View Article : Google Scholar : PubMed/NCBI

Jaskula-Sztul R, Chen G, Dammalapati A, Harrison A, Tang W, Gong S and Chen H: AB3-loaded and Tumor-targeted unimolecular micelles for medullary thyroid cancer treatment. J Mater Chem B. 5:151–159. 2017. View Article : Google Scholar : PubMed/NCBI

Rao SN and Smallridge RC: Anaplastic thyroid cancer: An update. Best Pract Res Clin Endocrinol Metab. 37:1016782023. View Article : Google Scholar : PubMed/NCBI

Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, et al: Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 13:644–660. 2017. View Article : Google Scholar : PubMed/NCBI

Moreno F, Reyes C, Pineda CA, Castellanos G, Cálix F, Calderón J and Vasquez-Bonilla WO: Anaplastic thyroid carcinoma with unusual long-term survival: A case report. J Med Case Rep. 16:392022. View Article : Google Scholar : PubMed/NCBI

Davies L and Welch HG: Increasing incidence of thyroid cancer in the united states, 1973–2002. JAMA. 295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI

Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S and Antonelli A: Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 79:180–196. 2022. View Article : Google Scholar : PubMed/NCBI

Al-Mohanna M, Alraouji NN, Alhabardi SA, Al-Mohanna F, Al-Otaibi B, Al-Jammaz I and Aboussekhra A: The curcumin analogue PAC has potent anti-anaplastic thyroid cancer effects. Sci Rep. 13:42172023. View Article : Google Scholar : PubMed/NCBI

Anderson RJ, Sizemore GW, Wahner HW and Carney JA: Thyroid scintigram in familial medullary carcinoma of the thyroid gland. Clin Nucl Med. 3:147–151. 1978. View Article : Google Scholar : PubMed/NCBI

Ballal S, Yadav MP, Moon ES, Rösch F, ArunRaj ST, Agarwal S, Tripathi M, Sahoo RK and Bal C: First-in-Human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer. Clin Nucl Med. 47:e444–e445. 2022. View Article : Google Scholar : PubMed/NCBI

Bao L, Li Y, Hu X, Gong Y, Chen J, Huang P, Tan Z, Ge M and Pan Z: Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer. Int Immunopharmacol. 133:1121022024. View Article : Google Scholar : PubMed/NCBI

Biermann K, Biersack HJ, Sabet A and Janzen V: Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nucl Med. 41:139–148. 2011. View Article : Google Scholar : PubMed/NCBI

Ceolin L, Duval M, Benini AF, Ferreira CV and Maia AL: Medullary thyroid carcinoma beyond surgery: Advances, challenges, and perspectives. Endocr Relat Cancer. 26:R499–R518. 2019. View Article : Google Scholar : PubMed/NCBI

Chintakuntlawar AV, Foote RL, Kasperbauer JL and Bible KC: Diagnosis and management of anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 48:269–284. 2019. View Article : Google Scholar : PubMed/NCBI

Choi YS, Jeon MJ, Doolittle WKL, Song DE, Kim K, Kim WB and Kim WG: Macrophage-induced carboxypeptidase A4 promotes the progression of anaplastic thyroid cancer. Thyroid. 34:1150–1162. 2024. View Article : Google Scholar : PubMed/NCBI

Contarino A, Dolci A, Maggioni M, Porta FM, Lopez G, Verga U, Elli FM, Iofrida EF, Cantoni G, Mantovani G, et al: Is encapsulated medullary thyroid carcinoma associated with a better prognosis? A case series and a review of the literature. Front Endocrinol (Lausanne). 13:8665722022. View Article : Google Scholar : PubMed/NCBI

Cristinziano L, Modestino L, Loffredo S, Varricchi G, Braile M, Ferrara AL, de Paulis A, Antonelli A, Marone G and Galdiero MR: Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J Immunol. 204:1362–1372. 2020. View Article : Google Scholar : PubMed/NCBI

D'Aprile S, Denaro S, Pavone AM, Giallongo S, Giallongo C, Distefano A, Salvatorelli L, Torrisi F, Giuffrida R, Forte S, et al: Anaplastic thyroid cancer cells reduce CD71 levels to increase iron overload tolerance. J Transl Med. 21:7802023. View Article : Google Scholar : PubMed/NCBI

Doolittle WKL, Zhao L and Cheng SY: Blocking CDK7-mediated NOTCH1-cMYC Signaling attenuates cancer stem cell activity in anaplastic thyroid cancer. Thyroid. 32:937–948. 2022. View Article : Google Scholar : PubMed/NCBI

Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, Greenberg JA, Zhang T, He B, Finnerty BM, et al: CSPG4 is a potential therapeutic target in anaplastic thyroid cancer. Thyroid. 31:1481–1493. 2021.PubMed/NCBI

Harach HR and Williams ED: Glandular (tubular and follicular) variants of medullary carcinoma of the thyroid. Histopathology. 7:83–97. 1983. View Article : Google Scholar : PubMed/NCBI

Hu Y, Wen Q, Cai Y, Liu Y, Ma W, Li Q, Song F, Guo Y, Zhu L, Ge J, et al: Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway. Phytomedicine. 108:1545282023. View Article : Google Scholar : PubMed/NCBI

Li C, Zhang H, Li S, Zhang D, Li J, Dionigi G, Liang N and Sun H: Prognostic impact of inflammatory markers PLR, LMR, PDW, MPV in medullary thyroid carcinoma. Front Endocrinol (Lausanne). 13:8618692022. View Article : Google Scholar : PubMed/NCBI

Li Q, Zhang L, Lang J, Tan Z, Feng Q, Zhu F, Liu G, Ying Z, Yu X, Feng H, et al: Lipid-peptide-mRNA nanoparticles augment radioiodine uptake in anaplastic thyroid cancer. Adv Sci (Weinh). 10:e22043342023. View Article : Google Scholar : PubMed/NCBI

Li Y: Pyrvinium pamoate can overcome artemisinin's resistance in anaplastic thyroid cancer. BMC Complement Med Ther. 21:1562021. View Article : Google Scholar : PubMed/NCBI

Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Shiau CK, Pan T, Yan Y, Tran TM, et al: Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest. 133:e1696532023. View Article : Google Scholar : PubMed/NCBI

Lu YL, Huang YT, Wu MH, Chou TC, Wong R and Lin SF: Efficacy of adavosertib therapy against anaplastic thyroid cancer. Endocr Relat Cancer. 28:311–324. 2024. View Article : Google Scholar : PubMed/NCBI

Ma B, Luo Y, Xu W, Han L, Liu W, Liao T, Yang Y and Wang Y: LINC00886 negatively regulates malignancy in anaplastic thyroid cancer. Endocrinology. 164:bqac2042023. View Article : Google Scholar : PubMed/NCBI

Matrone A, Gambale C, Prete A and Elisei R: Sporadic medullary thyroid carcinoma: Towards a precision medicine. Front Endocrinol (Lausanne). 13:8642532022. View Article : Google Scholar : PubMed/NCBI

Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, et al: Familial medullary thyroid carcinoma with noncysteine ret mutations: Phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab. 86:3746–3753. 2001. View Article : Google Scholar : PubMed/NCBI

Pan Z, Bao L, Lu X, Hu X, Li L, Chen J, Jin T, Zhang Y, Tan Z, Huang P and Ge M: IL2RA+VSIG4+ tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer. Biochim Biophys Acta Mol Basis Dis. 1869:1665912023. View Article : Google Scholar : PubMed/NCBI

Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, et al: Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 24:3059–3068. 2018. View Article : Google Scholar : PubMed/NCBI

Pusztaszeri MP, Bongiovanni M and Faquin WC: Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol. 21:26–35. 2014. View Article : Google Scholar : PubMed/NCBI

Rougier P, Parmentier C, Laplanche A, Lefevre M, Travagli JP, Caillou B, Schlumberger M, Lacour J and Tubiana M: Medullary thyroid carcinoma: Prognostic factors and treatment. Int J Radiat Oncol Biol Phys. 9:161–169. 1983. View Article : Google Scholar : PubMed/NCBI

Shakiba E, Boroomand S, Kheradmand Kia S and Hedayati M: MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: Potential therapeutic targets and diagnostic/prognostic markers and web based tools. Oncol Res. 32:1011–1019. 2024. View Article : Google Scholar : PubMed/NCBI

Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, et al: Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): A randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol. 24:175–186. 2023. View Article : Google Scholar : PubMed/NCBI

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, et al: Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 36:7–13. 2018. View Article : Google Scholar : PubMed/NCBI

Sugarman AJ, Huynh LD, Shabro A and Di Cristofano A: Anaplastic thyroid cancer cells upregulate mitochondrial one-carbon metabolism to meet purine demand, eliciting a critical targetable vulnerability. Cancer Lett. 568:2163042023. View Article : Google Scholar : PubMed/NCBI

Tang J, Luo Y and Xiao L: USP26 promotes anaplastic thyroid cancer progression by stabilizing TAZ. Cell Death Dis. 13:3262022. View Article : Google Scholar : PubMed/NCBI

Wang X, Ying T, Yuan J, Wang Y, Su X, Chen S, Zhao Y, Zhao Y, Sheng J, Teng L, et al: BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation. Endocr Relat Cancer. 30:e2203442023. View Article : Google Scholar : PubMed/NCBI

Wu J, Liang J, Liu R, Lv T, Fu K, Jiang L, Ma W, Pan Y, Tan Z, Liu Q, et al: Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer. Endocr Relat Cancer. 30:2300362023. View Article : Google Scholar : PubMed/NCBI

Zaballos MA, Acuña-Ruiz A, Morante M, Riesco-Eizaguirre G, Crespo P and Santisteban P: Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer. Cell Mol Life Sci. 79:5042022. View Article : Google Scholar : PubMed/NCBI

Zhang W, Ji W and Zhao X: MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1. BMC Cancer. 19:10932019. View Article : Google Scholar : PubMed/NCBI

Zhao Q, Feng H, Yang Z, Liang J, Jin Z, Chen L, Zhan L, Xuan M, Yan J, Kuang J, et al: The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer. Clin Transl Med. 12:e7272022. View Article : Google Scholar : PubMed/NCBI

Zhao Z, Yin XD, Zhang XH, Li ZW and Wang DW: Comparison of pediatric and adult medullary thyroid carcinoma based on SEER program. Sci Rep. 10:133102020. View Article : Google Scholar : PubMed/NCBI

Alhejaily AG, Alhuzim O and Alwelaie Y: Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (review). Mol Clin Oncol. 19:992023PubMed/NCBI

Zhao Y, Yu Z, Song Y, Fan L, Lei T, He Y and Hu S: The regulatory network of CREB3L1 and its roles in physiological and pathological conditions. Int J Med Sci. 21:123–136. 2024. View Article : Google Scholar : PubMed/NCBI

Pan Z, Xu T, Bao L, Hu X, Jin T, Chen J, Chen J, Qian Y, Lu X, Li L, et al: CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment. Mol Cancer. 21:1902022. View Article : Google Scholar : PubMed/NCBI

Haroon Al Rasheed MR and Xu B: Molecular alterations in thyroid carcinoma. Surg Pathol Clin. 12:921–930. 2019. View Article : Google Scholar : PubMed/NCBI

Misiak D, Bauer M, Lange J, Haase J, Braun J, Lorenz K, Wickenhauser C and Hüttelmaier S: MiRNA deregulation distinguishes anaplastic thyroid carcinoma (ATC) and supports upregulation of oncogene expression. Cancers (Basel). 13:59132021. View Article : Google Scholar : PubMed/NCBI

Vosgha H, Ariana A, Smith RA and Lam AK: miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma. Endocr Relat Cancer. 25:323–337. 2018. View Article : Google Scholar : PubMed/NCBI

Hou X, Chen C, He X and Lan X: Siglec-15 silencing inhibits cell proliferation and promotes cell apoptosis by inhibiting STAT1/STAT3 signaling in anaplastic thyroid carcinoma. Dis Markers. 2022:16064042022. View Article : Google Scholar : PubMed/NCBI

Pan Z, Lu X, Xu T, Chen J, Bao L, Li Y, Gong Y, Che Y, Zou X, Tan Z, et al: Epigenetic inhibition of CTCF by HN1 promotes dedifferentiation and stemness of anaplastic thyroid cancer. Cancer Lett. 580:2164962024. View Article : Google Scholar : PubMed/NCBI

Jiao C, Li L, Zhang P, Zhang L, Li K, Fang R, Yuan L, Shi K, Pan L, Guo Q, et al: REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway. Cell Death Differ. 27:497–508. 2020. View Article : Google Scholar : PubMed/NCBI

Zhong Y, Yu F, Yang L, Wang Y, Liu L, Jia C, Cai H, Yang J, Sheng S, Lv Z, et al: HOXD9/miR-451a/PSMB8 axis is implicated in the regulation of cell proliferation and metastasis via PI3K/AKT signaling pathway in human anaplastic thyroid carcinoma. J Transl Med. 21:8172023. View Article : Google Scholar : PubMed/NCBI

Fuziwara CS, Saito KC and Kimura ET: Thyroid follicular cell loss of differentiation induced by MicroRNA miR-17-92 cluster is attenuated by CRISPR/Cas9n gene silencing in anaplastic thyroid cancer. Thyroid. 30:81–94. 2020. View Article : Google Scholar : PubMed/NCBI

Xu B and Ghossein RA: Advances in thyroid pathology: High grade follicular Cell-derived thyroid carcinoma and anaplastic thyroid carcinoma. Adv Anat Pathol. 30:3–10. 2023. View Article : Google Scholar : PubMed/NCBI

Pan Z, Fang Q, Li L, Zhang Y, Xu T, Liu Y, Zheng X, Tan Z, Huang P and Ge M: HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1. Cancer Lett. 501:31–42. 2021. View Article : Google Scholar : PubMed/NCBI

Xu D, Yu J, Yang Y, Du Y, Lu H, Zhang S, Feng Q, Yu Y, Hao L, Shao J and Chen L: RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex. Cell Biosci. 13:362023. View Article : Google Scholar : PubMed/NCBI

Angela De Stefano M, Porcelli T, Ambrosio R, Luongo C, Raia M, Schlumberger M and Salvatore D: Type 2 deiodinase is expressed in anaplastic thyroid carcinoma and its inhibition causes cell senescence. Endocr Relat Cancer. 30:e2300162023. View Article : Google Scholar : PubMed/NCBI

Xu S, Cheng X, Wu L, Zheng J, Wang X, Wu J, Yu H, Bao J and Zhang L: Capsaicin induces mitochondrial dysfunction and apoptosis in anaplastic thyroid carcinoma cells via TRPV1-mediated mitochondrial calcium overload. Cell Signal. 75:1097332020. View Article : Google Scholar : PubMed/NCBI

Shi XZ, Zhao S, Wang Y, Wang MY, Su SW, Wu YZ and Xiong C: Antitumor activity of berberine by activating autophagy and apoptosis in CAL-62 and BHT-101 anaplastic thyroid carcinoma cell lines. Drug Des Devel Ther. 17:1889–1906. 2023. View Article : Google Scholar : PubMed/NCBI

Zheng H, Lin Q and Rao Y: A-Kinase interacting protein 1 knockdown restores chemosensitivity via inactivating PI3K/AKT and β-catenin pathways in anaplastic thyroid carcinoma. Front Oncol. 12:8547022022. View Article : Google Scholar : PubMed/NCBI

Gao H, Wang W and Li Q: GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma. Cancer Biol Ther. 23:369–377. 2022. View Article : Google Scholar : PubMed/NCBI

Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A and Suzuki S: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 36:1247–1254. 2012. View Article : Google Scholar : PubMed/NCBI

Califano I, Smulever A, Jerkovich F and Pitoia F: Advances in the management of anaplastic thyroid carcinoma: Transforming a life-threatening condition into a potentially treatable disease. Rev Endocr Metab Disord. 25:123–147. 2023. View Article : Google Scholar : PubMed/NCBI

Kanematsu R, Hirokawa M, Tanaka A, Suzuki A, Higuchi M, Kuma S, Hayashi T and Miyauchi A: Evaluation of E-Cadherin and β-Catenin immunoreactivity for determining undifferentiated cells in anaplastic thyroid carcinoma. Pathobiology. 88:351–358. 2021. View Article : Google Scholar : PubMed/NCBI

Shao C, Li Z, Zhang C, Zhang W, He R, Xu J and Cai Y: Optical diagnostic imaging and therapy for thyroid cancer. Mater Today Bio. 17:1004412022. View Article : Google Scholar : PubMed/NCBI

Moon J, Lee JH, Roh J, Lee DH and Ha EJ: Contrast-enhanced CT-based radiomics for the differentiation of anaplastic or poorly differentiated thyroid carcinoma from differentiated thyroid carcinoma: A pilot study. Sci Rep. 13:45622023. View Article : Google Scholar : PubMed/NCBI

Haase J, Misiak D, Bauer M, Pazaitis N, Braun J, Pötschke R, Mensch A, Bell JL, Dralle H, Siebolts U, et al: IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis. Mod Pathol. 34:32–41. 2021. View Article : Google Scholar : PubMed/NCBI

Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, et al: Clinical utility of circulating Cell-Free DNA mutations in anaplastic thyroid carcinoma. Thyroid. 31:1235–1243. 2021. View Article : Google Scholar : PubMed/NCBI

Han PZ, Ye WD, Yu PC, Tan LC, Shi X, Chen XF, He C, Hu JQ, Wei WJ, Lu ZW, et al: A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. JCI Insight. 9:e1737122024.PubMed/NCBI

Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, Suzuki H, Hosoe Y, Furutake Y, Taki M, et al: CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. 7:e1572152022. View Article : Google Scholar : PubMed/NCBI

Wang J, Liang Y, Xue A, Xiao J, Zhao X, Cao S, Li P, Dong J, Li Y, Xu Z and Yang L: Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer. J Immunother Cancer. 12:e0096032024. View Article : Google Scholar : PubMed/NCBI

Han D, Lee AY, Kim T, Choi JY, Cho MY, Song A, Kim C, Shim JH, Kim HJ, Kim H, et al: Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters. J Clin Invest. 133:e1663572023. View Article : Google Scholar : PubMed/NCBI

Yang Z, Tian H, Chen X, Li B, Bai G, Cai Q, Xu J, Guo W, Wang S, Peng Y, et al: Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 15:90972024. View Article : Google Scholar : PubMed/NCBI

Liu B, Zhang Y, Wang D, Hu X and Zhang Z: Single-cell meta-analyses reveal responses of tumor-reactive CXCL13⁺ T cells to immune-checkpoint blockade. Nat Cancer. 3:1123–1136. 2022. View Article : Google Scholar : PubMed/NCBI

Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, Boeckx B, Vanden Bempt M, Nevelsteen I, Lambein K, et al: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 27:820–832. 2021. View Article : Google Scholar : PubMed/NCBI

Lucotti S, Ogitani Y, Kenific CM, Geri J, Kim YH, Gu J, Balaji U, Bojmar L, Shaashua L, Song Y, et al: Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin β2. Cell. 188:1642–1661.e24. 2025. View Article : Google Scholar : PubMed/NCBI

Gao SH, Liu SZ, Wang GZ and Zhou GB: CXCL13 in cancer and other diseases: Biological functions, clinical significance, and therapeutic opportunities. Life (Basel). 11:12822021.PubMed/NCBI

Sakai SA, Oyoshi H, Nakamura M, Taki T, Nomura K, Hojo H, Hirata H, Motegi A, Nakamura Y, Zenkoh J, et al: Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy. Br J Cancer. Jul 16–2025.doi: 10.1038/s41416-025-03088-0 (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

Zhu J, Yuan Y, Wan X, Yin D, Li R, Chen W, Suo C and Song H: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 12:CD0113002021.PubMed/NCBI

Huang Y, Liang B, Chen X, Li Z, Deng Y, Du J, Zhong Y, Lin X, Fu J, Xie J, et al: Enhanced immunotherapy response in lung adenocarcinoma patients with COPD: Insights into tumor cells and immune microenvironment characteristics. Cell Commun Signal. 23:3242025. View Article : Google Scholar : PubMed/NCBI

Siyuan D, Han Z, Zhaopei L, Kaifeng J, Wenbin J, Zewei W, Zhiyuan L, Ying X, Jiajun W, Yuan C, et al: Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J Immunother Cancer. 9:e0018232021. View Article : Google Scholar

Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, et al: Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 31:1076–1085. 2021. View Article : Google Scholar : PubMed/NCBI

Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, et al: Neoadjuvant BRAF- and Immune-directed therapy for anaplastic thyroid carcinoma. Thyroid. 28:945–951. 2018. View Article : Google Scholar : PubMed/NCBI

Yang Y, Li S, Wang Y, Zhao Y and Li Q: Protein tyrosine kinase inhibitor resistance in malignant tumors: Molecular mechanisms and future perspective. Signal Transduct Target Ther. 7:3292022. View Article : Google Scholar : PubMed/NCBI

Choi YS, Kwon H, You MH, Kim TY, Kim WB, Shong YK, Jeon MJ and Kim WG: Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. Endocr Relat Cancer. 29:307–319. 2022. View Article : Google Scholar : PubMed/NCBI

Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, et al: PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 38:2620–2627. 2020. View Article : Google Scholar : PubMed/NCBI

Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, et al: Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 24:97–106. 2017. View Article : Google Scholar : PubMed/NCBI

Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, Castagna MG and Toti P: Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine. 64:122–129. 2019. View Article : Google Scholar : PubMed/NCBI

Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL and Cabanillas ME: Checkpoint inhibition in addition to Dabrafenib/Trametinib for BRAF(V600E)-Mutated anaplastic thyroid carcinoma. Thyroid. 34:336–346. 2024. View Article : Google Scholar : PubMed/NCBI

Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, et al: CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin Cancer Res. 23:7569–7583. 2017. View Article : Google Scholar : PubMed/NCBI

Zhang P, Tao C, Shimura T, Huang AC, Kong N, Dai Y, Yao S, Xi Y, Wang X, Fang J, et al: ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma. iScience. 26:1072722023. View Article : Google Scholar : PubMed/NCBI

Huang S, Zhang L, Xu M, Li C, Fu H, Huang J, Jin X, Liang S and Wang H: Co-Delivery of ¹³¹ I and Prima-1 by Self-Assembled CD44-Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics. Adv Healthc Mater. 10:e20010292021. View Article : Google Scholar : PubMed/NCBI

Landa I and Cabanillas ME: Genomic alterations in thyroid cancer: Biological and clinical insights. Nat Rev Endocrinol. 20:93–110. 2024. View Article : Google Scholar : PubMed/NCBI

Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–99. 2013. View Article : Google Scholar : PubMed/NCBI

Bhattacharya S, Mahato RK, Singh S, Bhatti GK, Mastana SS and Bhatti JS: Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches. Life Sci. 332:1221102023. View Article : Google Scholar : PubMed/NCBI

Shay JW, Homma N, Zhou R, Naseer MI, Chaudhary AG, Al-Qahtani M, Hirokawa N, Goudarzi M, Fornace AJ Jr, Baeesa S, et al: Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015): Jeddah, Kingdom of Saudi Arabia. 30 November-3 December 2015. BMC Genomics. 17 (Suppl 6):S4872016. View Article : Google Scholar

Guo M, Sun Y, Wei Y, Xu J and Zhang C: Advances in targeted therapy and biomarker research in thyroid cancer. Front Endocrinol (Lausanne). 15:13725532024. View Article : Google Scholar : PubMed/NCBI

Sekihara K, Himuro H, Toda S, Saito N, Hirayama R, Suganuma N, Sasada T and Hoshino D: Recent trends and potential of radiotherapy in the treatment of anaplastic thyroid cancer. Biomedicines. 12:12862024. View Article : Google Scholar : PubMed/NCBI

Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Xing Z, Liu T, Tang M, Mi L, Zhu J, Wu W and Wei T: Targeted therapy and drug resistance in thyroid cancer. Eur J Med Chem. 238:1145002022. View Article : Google Scholar : PubMed/NCBI

Zhang L, Feng Q, Wang J, Tan Z, Li Q and Ge M: Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities. Biochim Biophys Acta Rev Cancer. 1878:1889282023. View Article : Google Scholar : PubMed/NCBI

Deshmukh VG, Sapkal SB, Gadekar SS and Deshmukh V: EGFR inhibitors across generations: Progress, challenges, and future directions. J Mol Structure. 13392025.

Chen MF, Repetto M, Wilhelm C and Drilon A: RET Inhibitors in RET Fusion-positive lung cancers: Past, present, and future. Drugs. 84:1035–1053. 2024. View Article : Google Scholar : PubMed/NCBI

Krajewska J, Paliczka-Cieslik E and Jarzab B: Managing tyrosine kinase inhibitors side effects in thyroid cancer. Expert Rev Endocrinol Metab. 12:117–127. 2017. View Article : Google Scholar : PubMed/NCBI

Li J and Yu Y: POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation. Endocrine. 87:220–233. 2025. View Article : Google Scholar : PubMed/NCBI

Jiang S, Huang Y, Li Y, Gu Q, Jiang C, Tao X and Sun J: Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells. Endocrine. 79:86–97. 2023. View Article : Google Scholar : PubMed/NCBI

Ma W, Tian M, Hu L, Ruan X, Zhang W, Zheng X and Gao M: Early combined SHP2 targeting reverses the therapeutic resistance of vemurafenib in thyroid cancer. J Cancer. 14:1592–1604. 2023. View Article : Google Scholar : PubMed/NCBI

Cavallo MR, Yo JC, Gallant KC, Cunanan CJ, Amirfallah A, Daniali M, Sanders AB, Aplin AE, Pribitkin EA and Hartsough EJ: Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma. Cell Death Discov. 10:1752024. View Article : Google Scholar : PubMed/NCBI

Hou X, Dong Q, Hao J, Liu M, Ning J, Tao M, Wang Z, Guo F, Huang D, Shi X, et al: NSUN2-mediated m(5)C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2/SRSF6/UAP1 signaling axis. Theranostics. 15:2757–2777. 2025. View Article : Google Scholar : PubMed/NCBI

Molteni E, Baldan F, Damante G and Allegri L: GSK2801 reverses paclitaxel resistance in anaplastic thyroid cancer cell lines through MYCN downregulation. Int J Mol Sci. 24:59932023. View Article : Google Scholar : PubMed/NCBI

Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, et al: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial. Nat Med. 29:1103–1112. 2023. View Article : Google Scholar : PubMed/NCBI

Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Toyoshima M, et al: A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-Mutated thyroid cancer in Japan. Thyroid. 34:467–476. 2024.PubMed/NCBI

Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, et al: Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: A nonrandomized clinical trial. JAMA Oncol. 10:1672–1680. 2024. View Article : Google Scholar : PubMed/NCBI

Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, et al: Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer. 173:210–218. 2022. View Article : Google Scholar : PubMed/NCBI

Loo E, Khalili P, Beuhler K, Siddiqi I and Vasef MA: BRAF V600E mutation across multiple tumor types: Correlation between DNA-based sequencing and Mutation-specific immunohistochemistry. Appl Immunohistochem Mol Morphol. 26:709–713. 2018. View Article : Google Scholar : PubMed/NCBI

Cece A, Agresti M, De Falco N, Sperlongano P, Moccia G, Luongo P, Miele F, Allaria A, Torelli F, Bassi P, et al: Role of artificial intelligence in thyroid cancer diagnosis. J Clin Med. 14:24222025. View Article : Google Scholar : PubMed/NCBI